Popular GLP-1 medications used for weight loss and type 2 diabetes (such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity) have been linked to an unexpected problem involving fingernails. A multinational study found that people taking these drugs were more than four times as likely to report nail detachment, a condition in which the nail separates from the skin underneath it.
Researchers found that 39% of GLP-1 users experienced nail detachment, compared with just 9% of people who had never taken the medications. Nail discoloration was also considerably more common, and two-thirds (66%) of users reported at least one nail disorder.
The findings, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, come from the first controlled study to investigate the possible relationship between GLP-1 medications and nail health.
Unexpected Nail Problems Among GLP-1 Users
GLP-1 receptor agonists have become increasingly popular for managing obesity and type 2 diabetes. These medications act on a hormone signaling system that helps regulate blood sugar and appetite, making them effective tools for improving metabolic health and supporting weight loss.
However, scientists are still investigating their potential effects on other parts of the body. Until recently, information about nail changes during GLP-1 treatment came primarily from individual reports of possible adverse reactions, rather than controlled comparisons.
To investigate the connection, researchers examined 575 people using GLP-1 medications and compared them with 1,329 individuals who had type 2 diabetes and/or obesity but had never used the drugs. Participants were recruited from France, the United States, Brazil, and Mexico.
The results revealed a consistent pattern. Overall, 66% of GLP-1 users reported at least one nail disorder, compared with 53% of the control group. Nail discoloration showed an especially large difference, affecting 46% of users versus 17% of nonusers.
Nail detachment was even more striking, with reports more than four times as common among those taking GLP-1 medications.
Weight Loss Alone May Not Explain the Nail Changes
One important question was whether the nail problems might simply be related to weight loss, rather than to the medications themselves. Rapid changes in body weight can affect nutrition and other physiological processes, potentially influencing nail and hair health.
However, the researchers found that weight loss did not fully account for the differences. Even when they limited their analysis to participants who had lost weight, GLP-1 users continued to report significantly more nail problems than those who had not used the medications.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” said study author Dr. Charles Taïeb. “Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
The researchers emphasized that their findings do not prove that GLP-1 drugs cause nail disorders. Approximately half of the medication users said they had experienced nail problems even before beginning treatment.
When the researchers accounted for existing skin conditions and nutritional deficiencies, some of the differences between the groups became smaller. Nevertheless, nail detachment and discoloration remained approximately two to three times more common among GLP-1 users after these adjustments.
Scientists Also Find Higher Rates of Hair Loss and Scalp Problems
The unexpected findings were not limited to fingernails.
A companion study examining the same participants identified significant differences in hair and scalp health among people taking GLP-1 medications.
Half of GLP-1 users reported unusual hair loss, compared with 34% of nonusers. Reduced hair volume or density was also substantially more common, affecting 42% of users versus 19% of the control group.
Researchers additionally examined hair loss that began after treatment started. This was reported by 26% of GLP-1 users, compared with 12% of nonusers, making it more than twice as common in the medication group.
Scalp redness was approximately three times more frequent among GLP-1 users.
A particularly interesting finding was that hair loss rarely appeared by itself. Most users who reported shedding also experienced other scalp symptoms, including itching, redness or flaking skin.
These accompanying symptoms raised the possibility that inflammation could be contributing to the changes, rather than the hair loss being explained entirely by rapid weight reduction.
“This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component,” explained study author Dr. Bruno Halioua. “Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable. Taken together, our findings suggest that factors beyond weight loss alone may contribute to the hair, scalp and nail changes observed among GLP-1 users.”
What the Findings Mean for People Taking GLP-1 Drugs
Despite the relatively high frequency of reported symptoms, the researchers stressed that the findings should encourage awareness rather than alarm.
“These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” he said. “Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”
There are also important limitations to consider. Both investigations were cross-sectional studies, meaning they examined participants’ experiences without following them over time to establish how symptoms developed. The findings also relied on symptoms reported by participants rather than standardized clinical examinations.
As a result, the studies can reveal patterns and associations, but they cannot determine whether GLP-1 medications directly caused the reported nail, hair, or scalp problems.
To investigate these questions more thoroughly, the research team plans to conduct prospective studies that follow patients from the beginning of treatment. These investigations will include standardized skin, hair and nail examinations along with biological monitoring.
The goal is to establish when the changes first appear, identify the mechanisms behind them, and determine whether they improve or disappear over time.
The research received institutional support from DUCRAY Laboratories (Pierre Fabre Group), a company specializing in dermatological and hair care products developed to help manage skin and scalp conditions and improve quality of life.
